Compare Novartis AG (NVS) vs Visa Inc (V) Price & Performance

Novartis AGTrade

Visa IncTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Visa Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Visa Inc trades at $356.1 (market cap $685.71B). The key difference: Visa Inc is far larger — about 2.4× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	NVS	V
Market Cap	$290.25B	$685.71B
Sector	Health	Financials
52-Week High	$168.62	$365.14
52-Week Low	$113.50	$295.52
Enterprise Value	$330.27B	$696.30B
Dividend Yield	3.17%	0.74%
Volume	—	10,431,336

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

No Aura AI signal available yet.

Visa Inc

Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $396.70. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding expectations. Revenue reached $40 billion in 2025, and net income margin stands at 51.68%, reflecting robust profitability. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.

Visa presents a favorable long-term investment opportunity due to its dominant market position, consistent earnings growth, and high profitability. Key risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional ownership increasing, the stock offers upside potential, though investors should monitor execution on AI initiatives and macroeconomic factors affecting consumer spending.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 22 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

Visa launches a stablecoin platform to manage and monetize digital money operations beyond card transactions.PYMNTS · 1 day agoBullish Visa, Google, and Stripe join x402 Foundation to enable AI-driven micropayments online.Proactive Investors · 4 days agoBullish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Visa Inc

Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.